HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VC701 compound

inhibits TSPO translocator protein; structure in first source

Also Known As:

(18F)VC701

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - VC701 compound: 2

Experts

1.	Coliva, Angela: 1 article (01/2021)
2.	De Bernardi, Elisabetta: 1 article (01/2021)
3.	Galli, Rossella: 1 article (01/2021)
4.	Jacobs, Andreas H: 1 article (01/2021)
5.	Lo Dico, Alessia: 1 article (01/2021)
6.	Martelli, Cristina: 1 article (01/2021)
7.	Moresco, Rosa Maria: 1 article (01/2021)
8.	Ottobrini, Luisa: 1 article (01/2021)
9.	Pieri, Valentina: 1 article (01/2021)
10.	Politi, Letterio S: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to Temozolomide (TMZ) and the ability of [18F]FLT (activity of thymidine kinase 1 related to cell proliferation) and [18F]VC701 (translocator protein, TSPO) Positron Emission Tomography (PET) radiotracers to predict tumor response to therapy. "
2.	Parkinson Disease (Parkinson's Disease) 09/22/2022 - "The resulting method was applied to a mouse model of Parkinson's disease subjected to a test-retest study (n = 6) with the TSPO-specific radioligand [18F]VC701. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Metformin (Glucophage)
3.	Temozolomide (Temodar)
4.	thymidine kinase 1
5.	alovudine

Related Therapies and Procedures

1.	Therapeutics